

## XIAO JIANG

Partner

Fangda Partners

+852 3976 8888

[xiao.jiang@fangdalaw.com](mailto:xiao.jiang@fangdalaw.com)



### PRACTICE AREAS

M&A, PRIVATE EQUITY AND GENERAL CORPORATE.

## REPRESENTATIVE MATTERS AND CASES

### M&A

- Represented Xing Ding Limited, a wholly owned subsidiary of Sino IC Leasing Co. Ltd., in its HKD 990 million acquisition of a controlling stake (67.82%) in Unisplendour Technology (Holdings) Limited (HKSE: 00365)
- Represented Joy City Property Limited (SEHK: 207) on the transfer of its equity interests in Shanghai Gaoxing Property Limited and Xi'an Qujiang Joy City to Garbo Commercial Property Fund L. P.
- Represented China Everbright Limited in its USD 126 million acquisition from Medtronic Inc. of 22.4% of the shares of HKSE-listed LifeTech Scientific Corporation, a leading cardiovascular device manufacturer
- Represented China National Bluestar Group Co. Ltd. in the restructuring of its silicone business for listing on the Oslo Exchange
- Represented Yufeng Medical Fund in selling its holding in ReLIA Bioengineering (Shenzhen) Co., Ltd. to Shanghai Runda Medical Technology Co. Ltd. (A-share stock code: 603108) for approximately USD 180 million
- Represented Shoutai Jinxin and Fangyuan Group in their acquisitions of the entire issued share capital of two SFC-licensed entities in Hong Kong
- Represented shareholders of AMS Pharmaceutical in selling the controlling stake of the company to Yantai Dongcheng Pharmaceutical Group Co., Ltd (A-share stock code: 002675)

- Represented Yunfeng Fund in its USD 56 million acquisition of ReLIA Diagnostics System Inc., a medical device manufacturer based in California, US
- Represented Alibaba Group and Zhenjiang Ant Small and Micro Financial Services Group Co., Ltd. in their formation of an off-shore O2O joint venture with a total investment of over RMB 2.7 billion
- Represented Shanghai Electric Group in its attempted acquisition of a Hong Kong-listed company and a privately held company controlled by the same party for over USD 200 million
- Represented China Integrated Circuit Industry Investment Fund Co., Ltd. in its HKD 3 billion investment in Semiconductor Manufacturing International Corporation
- Represented Anjue.com in its sale of the company to 58.tongcheng for USD 240 million
- Represented MII Co, Ltd., an investment vehicle of a Chinese company, in its acquisition of two companies in Hong Kong from a PE investment firm for USD 240 million
- Represented Chem China, Blackstone Group, and another US private equity investment fund in its bidding of New Pharm
- Represented China National BlueStar (Group) Co., Ltd. in its sale of stakes in its European subsidiaries to a Chinese investment firm in two separate transactions for a total of USD 500 million
- Represented Tingyi (Cayman Islands) Holding Corp in its strategic alliance with PepsiCo. Inc. in which PepsiCo transferred its bottling business in China to Tingyi's beverage subsidiary in exchange for a 5% shareholding in the subsidiary, which had a combined business totaling USD 12 billion
- Represented China National Development Bank in its USD 1.5 billion acquisition financing of China National BlueStar (Group) Co., Ltd.'s USD 2 billion acquisition of Elkem AS
- Represented ZTE Agrobusiness Company Limited in its proposed investment in an Indonesia agriculture company
- Represented China National Chemical Corporation in its bid for the agrochemical business of a major US chemical corporation
- Represented China National BlueStar (Group) Corporation in its sale of a 20% minority interest of the company to Blackstone Group for USD 600 million in cash, in its EUR 399 million cash acquisition of the silicone and sulfuric businesses of Rhodia SA (France), and in its USD 400 million cash acquisition of Drakkar Holdings S.A. (Belgium)

- Represented Yahoo! Inc. in its strategic investment in Alibaba.com Corporation, which had a combined business in China amounting to USD 4 billion
- Represented the independent non-executive directors of CNOOC Limited in connection with the proposed USD 18.5 billion acquisition of Unocal Corporation
- Represented Sina Corporation in its adoption of a shareholder rights plan in response to the unsolicited accumulation of a 19.5% interest by Shanda Interactive Entertainment Limited
- Represented Ispat Inland International N.V. in its USD 4.2 billion merger with International Steel Group in 2004
- Represented Cadbury Schweppes in its USD 4.2 billion acquisition of the confectionery business of Pfizer Inc.

#### Private equity

- Represented Autoflight Global Limited in its group restructuring and Series A financing of USD 5.38 million
- Represented China Electronics Corporation (BVI) Holdings Company Limited, the subsidiary of Huada Semiconductor Co., Ltd, on its acquisition of certain Series A Preferred Shares of Alpha Power Solutions Limited for USD 4.34 million
- Represented Zhenjiang Ant Small and Micro Financial Services Group Co., Ltd. in its series of investments in an online second-hand car sale and exchange platform company, a software service provider for insurance companies, and an infrastructure provider for internet financing, with a total investment over USD 120 million
- Represented Zhenjiang Ant Small and Micro Financial Services Group Co., Ltd. in their investment in Ebao Corporation
- Represented shareholders of Yuneec Group in their sale of a 15% minority stake in the company to Intel Capital for USD 60 million
- Represented Morningside Venture International Capital in its USD 15 million Series A investment in Luqa Ventures Co., Limited
- Represented Colony Capital in its acquisition of a commercial residence building in Beijing from Charm Way Profits Limited and in its subsequent sale of the building to Shimao Group

- Represented SIG China Investments One, Ltd. together with Qiming Venture Partners, L.P. and its affiliated funds in their equity investment in AllTech International Group, Inc.
- Represented Wafra Partners LLC together with Brown Brothers Harriman & Co. in their equity investment in CTM Group, Inc.
- Represented Deutsche Bank AG in its disposal of 27 portfolio investments
- Represented Boston Scientific Corporation in its equity investment in Osiris Acquisition II, Inc.
- Represented DND Partners LLC in its equity investment in The Tennis Channel, Inc.

## **OTHER INFORMATION**

### **Education**

- Columbia University School of Law, J.D., 2002, Harlan Fiske Stone Scholar
- Temple University, M.B.A., 1997, Dean's Certificate of Excellence
- Beijing International Studies University, B.A., 1993, with distinctions

### **Professional Qualification**

- Admitted to practice in New York (2003)
- Admitted to practice in Hong Kong SAR (2013)

### **Professional Background**

Ms. Jiang is a partner of the Hong Kong office of Fangda Partners. Ms. Jiang's practice focuses on cross-border M&A, private equity transactions and general corporate work. She has represented numerous Chinese corporate clients in their overseas acquisitions in a wide variety of industries. She has also assisted private equity funds and financial institutions in their many minority investments and financing transactions.

Before joining Fangda Partners, Ms. Jiang worked at international law firms in New York and Hong Kong. Ms. Jiang is fluent in English and Mandarin Chinese.